\documentclass[11pt,twoside]{article}\makeatletter

\IfFileExists{xcolor.sty}%
  {\RequirePackage{xcolor}}%
  {\RequirePackage{color}}
\usepackage{colortbl}
\usepackage{wrapfig}
\usepackage{ifxetex}
\ifxetex
  \usepackage{fontspec}
  \usepackage{xunicode}
  \catcode`⃥=\active \def⃥{\textbackslash}
  \catcode`❴=\active \def❴{\{}
  \catcode`❵=\active \def❵{\}}
  \def\textJapanese{\fontspec{Noto Sans CJK JP}}
  \def\textChinese{\fontspec{Noto Sans CJK SC}}
  \def\textKorean{\fontspec{Noto Sans CJK KR}}
  \setmonofont{DejaVu Sans Mono}
  
\else
  \IfFileExists{utf8x.def}%
   {\usepackage[utf8x]{inputenc}
      \PrerenderUnicode{–}
    }%
   {\usepackage[utf8]{inputenc}}
  \usepackage[english]{babel}
  \usepackage[T1]{fontenc}
  \usepackage{float}
  \usepackage[]{ucs}
  \uc@dclc{8421}{default}{\textbackslash }
  \uc@dclc{10100}{default}{\{}
  \uc@dclc{10101}{default}{\}}
  \uc@dclc{8491}{default}{\AA{}}
  \uc@dclc{8239}{default}{\,}
  \uc@dclc{20154}{default}{ }
  \uc@dclc{10148}{default}{>}
  \def\textschwa{\rotatebox{-90}{e}}
  \def\textJapanese{}
  \def\textChinese{}
  \IfFileExists{tipa.sty}{\usepackage{tipa}}{}
\fi
\def\exampleFont{\ttfamily\small}
\DeclareTextSymbol{\textpi}{OML}{25}
\usepackage{relsize}
\RequirePackage{array}
\def\@testpach{\@chclass
 \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else
  \ifnum \@lastchclass=7 5 \else
   \ifnum \@lastchclass=8 \tw@ \else
    \ifnum \@lastchclass=9 \thr@@
   \else \z@
   \ifnum \@lastchclass = 10 \else
   \edef\@nextchar{\expandafter\string\@nextchar}%
   \@chnum
   \if \@nextchar c\z@ \else
    \if \@nextchar l\@ne \else
     \if \@nextchar r\tw@ \else
   \z@ \@chclass
   \if\@nextchar |\@ne \else
    \if \@nextchar !6 \else
     \if \@nextchar @7 \else
      \if \@nextchar (8 \else
       \if \@nextchar )9 \else
  10
  \@chnum
  \if \@nextchar m\thr@@\else
   \if \@nextchar p4 \else
    \if \@nextchar b5 \else
   \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi
   \fi \fi  \fi  \fi  \fi  \fi  \fi \fi \fi \fi \fi \fi}
\gdef\arraybackslash{\let\\=\@arraycr}
\def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}}
\def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}}
\def\abbr{}
\def\corr{}
\def\expan{}
\def\gap{}
\def\orig{}
\def\reg{}
\def\ref{}
\def\sic{}
\def\persName{}\def\name{}
\def\placeName{}
\def\orgName{}
\def\textcal#1{{\fontspec{Lucida Calligraphy}#1}}
\def\textgothic#1{{\fontspec{Lucida Blackletter}#1}}
\def\textlarge#1{{\large #1}}
\def\textoverbar#1{\ensuremath{\overline{#1}}}
\def\textquoted#1{‘#1’}
\def\textsmall#1{{\small #1}}
\def\textsubscript#1{\@textsubscript{\selectfont#1}}
\def\textxi{\ensuremath{\xi}}
\def\titlem{\itshape}
\newenvironment{biblfree}{}{\ifvmode\par\fi }
\newenvironment{bibl}{}{}
\newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par }
\newenvironment{citbibl}{}{\ifvmode\par\fi }
\newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi }
\newenvironment{docDate}{}{\ifvmode\par\fi }
\newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi }
\newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par }
\newenvironment{msHead}{\vskip 6pt}{\par}
\newenvironment{msItem}{\vskip 6pt}{\par}
\newenvironment{rubric}{}{}
\newenvironment{titlePart}{}{\par }

\newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}}
\newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}}
\newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}}
\newcolumntype{P}[1]{){\arraybackslash}p{#1}}
\newcolumntype{B}[1]{){\arraybackslash}b{#1}}
\newcolumntype{M}[1]{){\arraybackslash}m{#1}}
\definecolor{label}{gray}{0.75}
\def\unusedattribute#1{\sout{\textcolor{label}{#1}}}
\DeclareRobustCommand*{\xref}{\hyper@normalise\xref@}
\def\xref@#1#2{\hyper@linkurl{#2}{#1}}
\begingroup
\catcode`\_=\active
\gdef_#1{\ensuremath{\sb{\mathrm{#1}}}}
\endgroup
\mathcode`\_=\string"8000
\catcode`\_=12\relax

\usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry}
\usepackage{framed}

\definecolor{shadecolor}{gray}{0.95}
\usepackage{longtable}
\usepackage[normalem]{ulem}
\usepackage{fancyvrb}
\usepackage{fancyhdr}
\usepackage{graphicx}
\usepackage{marginnote}

\renewcommand{\@cite}[1]{#1}


\renewcommand*{\marginfont}{\itshape\footnotesize}

\def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif}

  \pagestyle{fancy}

\usepackage[pdftitle={Enhancing Effect of Silver Nitrate Nanoparticles as an Adjuvant in Formulation of Polyvalent Foot and Mouth Disease Vaccine},
 pdfauthor={}]{hyperref}
\hyperbaseurl{}

	 \paperwidth210mm
	 \paperheight297mm
              
\def\@pnumwidth{1.55em}
\def\@tocrmarg {2.55em}
\def\@dotsep{4.5}
\setcounter{tocdepth}{3}
\clubpenalty=8000
\emergencystretch 3em
\hbadness=4000
\hyphenpenalty=400
\pretolerance=750
\tolerance=2000
\vbadness=4000
\widowpenalty=10000

\renewcommand\section{\@startsection {section}{1}{\z@}%
     {-1.75ex \@plus -0.5ex \@minus -.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\Large\bfseries}}
\renewcommand\subsection{\@startsection{subsection}{2}{\z@}%
     {-1.75ex\@plus -0.5ex \@minus- .2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\Large}}
\renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}%
     {-1.5ex\@plus -0.35ex \@minus -.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\large}}
\renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}%
     {-1ex \@plus-0.35ex \@minus -0.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\normalsize}}
\renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}%
     {1.5ex \@plus1ex \@minus .2ex}%
     {-1em}%
     {\reset@font\normalsize\bfseries}}


\def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt}
 \@tempdima 1.5em \begingroup
 \parindent \z@ \rightskip \@pnumwidth 
 \parfillskip -\@pnumwidth 
 \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par
 \endgroup}
\def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}}
\def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}}
\def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}}
\def\l@subparagraph{\@dottedtocline{5}{10em}{5em}}
\@ifundefined{c@section}{\newcounter{section}}{}
\@ifundefined{c@chapter}{\newcounter{chapter}}{}
\newif\if@mainmatter 
\@mainmattertrue
\def\chaptername{Chapter}
\def\frontmatter{%
  \pagenumbering{roman}
  \def\thechapter{\@roman\c@chapter}
  \def\theHchapter{\roman{chapter}}
  \def\thesection{\@roman\c@section}
  \def\theHsection{\roman{section}}
  \def\@chapapp{}%
}
\def\mainmatter{%
  \cleardoublepage
  \def\thechapter{\@arabic\c@chapter}
  \setcounter{chapter}{0}
  \setcounter{section}{0}
  \pagenumbering{arabic}
  \setcounter{secnumdepth}{6}
  \def\@chapapp{\chaptername}%
  \def\theHchapter{\arabic{chapter}}
  \def\thesection{\@arabic\c@section}
  \def\theHsection{\arabic{section}}
}
\def\backmatter{%
  \cleardoublepage
  \setcounter{chapter}{0}
  \setcounter{section}{0}
  \setcounter{secnumdepth}{2}
  \def\@chapapp{\appendixname}%
  \def\thechapter{\@Alph\c@chapter}
  \def\theHchapter{\Alph{chapter}}
  \appendix
}
\newenvironment{bibitemlist}[1]{%
   \list{\@biblabel{\@arabic\c@enumiv}}%
       {\settowidth\labelwidth{\@biblabel{#1}}%
        \leftmargin\labelwidth
        \advance\leftmargin\labelsep
        \@openbib@code
        \usecounter{enumiv}%
        \let\p@enumiv\@empty
        \renewcommand\theenumiv{\@arabic\c@enumiv}%
	}%
  \sloppy
  \clubpenalty4000
  \@clubpenalty \clubpenalty
  \widowpenalty4000%
  \sfcode`\.\@m}%
  {\def\@noitemerr
    {\@latex@warning{Empty `bibitemlist' environment}}%
    \endlist}

\def\tableofcontents{\section*{\contentsname}\@starttoc{toc}}
\parskip0pt
\parindent1em
\def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}}
\newenvironment{reflist}{%
  \begin{raggedright}\begin{list}{}
  {%
   \setlength{\topsep}{0pt}%
   \setlength{\rightmargin}{0.25in}%
   \setlength{\itemsep}{0pt}%
   \setlength{\itemindent}{0pt}%
   \setlength{\parskip}{0pt}%
   \setlength{\parsep}{2pt}%
   \def\makelabel##1{\itshape ##1}}%
  }
  {\end{list}\end{raggedright}}
\newenvironment{sansreflist}{%
  \begin{raggedright}\begin{list}{}
  {%
   \setlength{\topsep}{0pt}%
   \setlength{\rightmargin}{0.25in}%
   \setlength{\itemindent}{0pt}%
   \setlength{\parskip}{0pt}%
   \setlength{\itemsep}{0pt}%
   \setlength{\parsep}{2pt}%
   \def\makelabel##1{\upshape ##1}}%
  }
  {\end{list}\end{raggedright}}
\newenvironment{specHead}[2]%
 {\vspace{20pt}\hrule\vspace{10pt}%
  \phantomsection\label{#1}\markright{#2}%

  \pdfbookmark[2]{#2}{#1}%
  \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}%
  }{}
      \def\TheFullDate{2020 2020-01-15 (revised: 10 Year 2020 15 January 2020)}
\def\TheID{\makeatother }
\def\TheDate{2020 2020-01-15}
\title{Enhancing Effect of Silver Nitrate Nanoparticles as an Adjuvant in Formulation of Polyvalent Foot and Mouth Disease Vaccine}
\author{}\makeatletter 
\makeatletter
\newcommand*{\cleartoleftpage}{%
  \clearpage
    \if@twoside
    \ifodd\c@page
      \hbox{}\newpage
      \if@twocolumn
        \hbox{}\newpage
      \fi
    \fi
  \fi
}
\makeatother
\makeatletter
\thispagestyle{empty}
\markright{\@title}\markboth{\@title}{\@author}
\renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@
\belowdisplayskip \abovedisplayskip
\abovedisplayshortskip \z@ plus2\p@
\belowdisplayshortskip 4\p@ plus2\p@ minus2\p@
\def\@listi{\leftmargin\leftmargini
               \topsep 2\p@ plus1\p@ minus1\p@
               \parsep 2\p@ plus\p@ minus\p@
               \itemsep 1pt}
}
\makeatother
\fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm}
\fancyhf{} 
\setlength{\headheight}{14pt}
\fancyhead[LE]{\bfseries\leftmark} 
\fancyhead[RO]{\bfseries\rightmark} 
\fancyfoot[RO]{}
\fancyfoot[CO]{\thepage}
\fancyfoot[LO]{\TheID}
\fancyfoot[LE]{}
\fancyfoot[CE]{\thepage}
\fancyfoot[RE]{\TheID}
\hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true}
\fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}}

\date{}
\usepackage{authblk}

\providecommand{\keywords}[1]
{
\footnotesize
  \textbf{\textit{Index terms---}} #1
}

\usepackage{graphicx,xcolor}
\definecolor{GJBlue}{HTML}{273B81}
\definecolor{GJLightBlue}{HTML}{0A9DD9}
\definecolor{GJMediumGrey}{HTML}{6D6E70}
\definecolor{GJLightGrey}{HTML}{929497} 

\renewenvironment{abstract}{%
   \setlength{\parindent}{0pt}\raggedright
   \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}}
   \vskip16pt
   \textcolor{GJBlue}{\large\bfseries\abstractname\space}
}{%   
   \vskip8pt
   \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}}
   \vskip16pt
}

\usepackage[absolute,overlay]{textpos}

\makeatother 
      \usepackage{lineno}
      \linenumbers
      
\begin{document}

             \author[1]{Hind M.  Daoud}

             \author[2]{Sonia A.  Rizk}

             \author[3]{Nermeen G.  Shafik}

\renewcommand\Authands{ and }

\date{\small \em Received: 7 December 2019 Accepted: 31 December 2019 Published: 15 January 2020}

\maketitle


\begin{abstract}
        


Vaccination of susceptible animals against foot-and-mouth disease (FMD) is a wellestablished strategy to combat the disease. The protective immune response induced by vaccines can vary according to the kinds of adjuvants. The advance in nanotechnology has enabled us to utilize particles in the Nano size. So using novel immune adjuvants has an auxiliary role in the amplification of immune responses. Many investigators agree the size of the adjuvant particles is crucial to their adjuvant activities. The main aim of this study is to evaluate the effect of Silver nitrate nanoparticles (AgNPs) 5-10 nm particle size as an adjuvant in the polyvalent foot and mouth disease vaccine (containing FMD viruses O / PanAsia2, A/Iran 05, SAT2/VII/Lib-12 (SAT2/ Lib) and SAT2/VII/Ghb-12(SAT2/Ghb). A comprehensive immunological study was conducted in three calve groups vaccinated subcutaneously with three formulae of polyvalent FMD where group (A) was vaccine formula with AgNPs adjuvant, group (B) the vaccine formula adjuvanted with both MontanidISA 206 oil and AgNPs, while group (C) the vaccine formula with MontanidISA 206 oil adjuvant. A forth calve group kept without vaccination as control.

\end{abstract}


\keywords{}

\begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) 
\textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark}
\end{textblock*}

\begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) 
\textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}}
\end{textblock*}


\let\tabcellsep& 	 	 		 
\section[{Introduction}]{Introduction}\par
oot-and-Mouth Disease Virus (FMDV) is the pathological agent of the most important diseases that affect cloven-hoofed livestock. It is a small, non-enveloped single-stranded, positive-sense RNA virus related to the family Picornaviridae. FMD has seven serotypes: O, A, C, Asia 1, and Southern African Territories (SAT) 1, 2 and 3, they cause a highly contagious disease \hyperref[b0]{(Alexandersen et al., 2003)}. There are over 60 subtypes within these serotypes. For that, there are no universal vaccines, thus presenting challenges in the selection of vaccine strains \hyperref[b5]{(Brown, 2003 and}\hyperref[b1]{Arzt et al., 2011)}. Infection with FMDV leads to an acute disease that spreads very rapidly. It characterized by fever, lameness, and vesicular lesions on the feet, tongue, snout, and teats, also characterized by high morbidity but low mortality \hyperref[b14]{(Grubman and Baxt, 2004)}. Although vaccines extensively used to control FMD, there was no antiviral therapy to treat ongoing infections with FMD virus \hyperref[b13]{(Grubman, 2005)}.\par
The most effective FMD vaccines are consist of chemically inactivated FMDV. They can only offer complete protection after seven days of vaccination because of the time needed to trigger an immune response \hyperref[b28]{(Pacheco et al., 2015 and}\hyperref[b45]{Zhang et al., 2015)}.\par
As oil as an adjuvants is absorbed more slowly than its gel equivalent, also can cause local reaction in the site of vaccination. To prevent such effect, can use other adjuvant types than the oil, such as nanoparticles \hyperref[b4]{(Batista et al., 2010)}. Recently nanoparticles and micro carriers are used in vaccine delivery to enhance the cellular and humeral immunity through an increased presentation of vaccine epitopes to the antigenpresenting cell \hyperref[b33]{(Singh et al., 2010)}. The particles in the nanometer size range are of particular interest may be due to their unique cellular uptake and bio-distribution properties. They also play an important role when using as vaccine antigen carriers and adjuvants \hyperref[b29]{(Perni et al., 2014)}.\par
Silver nanoparticles (AgNPs) have attracted significant interest among the emerging Nano products because of their unique properties and increasing use for various applications in nanomedicine \hyperref[b12]{(Gurunathan et al., 2009)}. The adjuvanticity effect of AgNPs on rabies vaccine potency shown for the first time, and the results clearly showed the effect of AgNPs on increasing the humoral response to the rabies vaccine \hyperref[b38]{(Vahid et al., 2016)}. The immunological adjuvant effect of AgNPs investigated both in vitro and in vivo. The in vivo adjuvant effect of AgNPs evaluated with model antigen ovalbumin (OVA) and bovine serum albumin (BSA) in mice by intraperitoneal and subcutaneous immunization and the results showed the remarkable adjuvant effect of AgNPs. The result is beneficial for the future applications, especially in biomedicine \hyperref[b44]{(Xu et al., 2013)}.\par
This study was carried out to determine the adjuvant effects of Silver nitrate nanoparticles when used as an adjuvant to improve the polyvalent FMD vaccine on the immune response of calves. 
\section[{II.}]{II.}\par
Material and Methods 
\section[{Cell culture}]{Cell culture}\par
Cell line of Baby Hamster Kidney (BHK21) clone 13 was maintained in the Department of Foot and Mouth Disease Vaccine Research (DFMDVR), Veterinary Serum and Vaccine Research Institute (VSVRI), Abbasia, Cairo, according to the technique described by \hyperref[b23]{Macpherson and Stocher (1962)}, used for virus propagation and application of serum neutralization test. Using Eagle's medium with 8-10\% sterile new-born calf serum obtained from Sigma, USA. 
\section[{Virus propagation and concentration}]{Virus propagation and concentration}\par
FMD viruses O / PanAsia2, A/Iran 05, SAT2/VII/Lib-12 (SAT2/ Lib) and SAT2/VII/Ghb-12(SAT2/Ghb) are locally isolated strains of cattle origin. The viruses were typed at VSVRI and confirmed by Pirbright, International Reference Laboratories, United Kingdom and propagated on BHK cells then concentrated using polyethylene glycol 6000 (PEG-6000) according to \hyperref[b20]{Killington et al.(1996)} and \hyperref[b16]{Hiam and Eman (2010)}. The viral suspension was concentrated at 25,000 rpm for 5 hours at 4? in a high-speed centrifuge (Avanti J25, Beckman Coulter, and Fullerton, CA, USA). The virus in the bottom was removed and polled. It was further concentrated in an ultracentrifuge at 35,000 rpm /min for 3 hours at 4?. The viral pelted was polled and preserved at -80? to be used in vaccine preparation. Virus concentrations provide virus titers of 10 9 ; 10 9 ; 10 8.5 , and 10 9 TCID 50 /ml for O/PanAsia2, A/Iran 05, SAT2/VII/Lib-12 (SAT2/ Lib) and SAT2/VII/Ghb-12(SAT2/Ghb) respectively. 
\section[{FMD viruses inactivation}]{FMD viruses inactivation}\par
Complete inactivation 0f the concentrated virus stock using Binary Ethyleneimine (BEI) according to \hyperref[b2]{Bahnemann (1975)} and \hyperref[b17]{Ismail et al.(2013)}. 1\%M BEI in 0.2N NaOH was added to the virus suspension to give a final concentration of 0.001M of BEI. Mixed well the virus and BEI mixture, and the pH then adjusted to 8.0 by sodium bicarbonate. Incubation of the mixture at 37 o C for 12 hours.\par
Sodium thiosulphate added to give a final concentration of 2\% to neutralize the BEI action. The inactivated viruses used in the preparation of vaccine formulation with AgNPs, ISA 206 oil, and AgNPs with Montanide ISA 206oil adjuvants for animal immunization. 
\section[{Silver nanoparticles (AgNPs) characterization}]{Silver nanoparticles (AgNPs) characterization}\par
Sample of Silver nanoparticles (AgNPs) was prepared as 0.001M/ 10mls and subjected to continuous stirring for 6 hours at room temperature, followed by sonication for three times repeated cycles each of 15 minutes according to \hyperref[b37]{Udapudi et al.(2012)}. 
\section[{Measuring of Silver nanoparticles (AgNPs) size with}]{Measuring of Silver nanoparticles (AgNPs) size with}\par
Transmission Electron Microscopy (TEM) For transmission electron microscopy of the samples of Silver nanoparticles, prepared by dispersing in ultrapure H 2 O at about 10\% concentration and ultrasonicated at 1000L for 15 minutes. One drop of this liquid immediately transferred by a micropipette to a 3 mm diameter Formvar coated copper TEM grid, slowly evaporated to dryness. The samples on the TEM grid analyzed using a 100cx JEOL TEM at 80 kV at CURP, Giza, Egypt. 
\section[{Silver nanoparticles (AgNPs) cytotoxicity}]{Silver nanoparticles (AgNPs) cytotoxicity}\par
Baby Hamster Kidney cell line used to investigate the adjuvant inhibitory adverse effect on cell proliferation as an indicator of safety to use Silver nanoparticles (AgNPs) as a biocompatible adjuvant in the vaccine formulation. 
\section[{Montanide ISA 206}]{Montanide ISA 206}\par
The mineral oil-based adjuvant from water-in oilin-water (double emulsion) mixed with antigen w/w supplied by Seppic, Paris, France.  
\section[{FMD oil adjuvanted vaccine}]{FMD oil adjuvanted vaccine}\par
Formulation with oil phase carried out according to the method described by \hyperref[b3]{Barnett et al. (2003)}, and Wael et al.  {\ref (2014)} where the oil phase consisted of Montnide ISA 206 mixed with the inactivated viruses as equal parts of an aqueous and oil phase (w/ w) and mixed thoroughly. 
\section[{FMD oil and Silver nanoparticles (AgNPs) adjuvanted vaccine}]{FMD oil and Silver nanoparticles (AgNPs) adjuvanted vaccine}\par
The inactivated viruses adjuvanted with ISA 206 oil (w/ w), and AgNPs in a concentration of0.1 mg/dose. 
\section[{Animalgroups}]{Animalgroups}\par
Twelve local breed healthy calves and free from antibodies against FMD viruses as proved by using SNT and ELISA were used in this study where they were divided into four groups (3calves/group) as follow:\par
Group(A): vaccinated with the inactivated polyvalent FMD vaccine adjuvanted with AgNPs vaccine. 
\section[{Group(B): vaccinated with the inactivated polyvalent FMD vaccine adjuvanted with both oil and AgNPs vaccine.}]{Group(B): vaccinated with the inactivated polyvalent FMD vaccine adjuvanted with both oil and AgNPs vaccine.}\par
Group (C): vaccinated with the inactivated polyvalent FMD vaccine adjuvanted with oil adjuvant vaccine. 
\section[{Group (D): was kept none vaccinated as a control group.}]{Group (D): was kept none vaccinated as a control group.}\par
All vaccinated animals received 3ml/animal of the used vaccine formula inoculated subcutaneously. 
\section[{Sampling}]{Sampling}\par
Blood samples were collected from all calf's groups on an anticoagulant for evaluation of cell 2 Year 2020 mediated immunity using Lymphocyte blastogenesis assay on the 3 rd day post-vaccination, then every week up to 10 weeks.\par
Serum samples were collected for the serological tests (SNT and ELISA), weekly for one month then every 2 weeks up to 40 weeks post-vaccination and stored at -20 o C until used. The test was performed by the micro titer technique as described by \hyperref[b11]{Ferreira (1976)}, and the antibody titer expressed as serum neutralization log10.\par
13. Indirect Enzyme-linked immunosrobent assay (ELISA) It was carried out according to the method described by \hyperref[b40]{Voller et al. (1976)} and OIE (2012). Serum samples were examined for FMD viral specific IgG antibodies using in-house developed ELISA assay. 
\section[{III.}]{III.} 
\section[{Results}]{Results} 
\section[{a) Confirmation of complete virus inactivation}]{a) Confirmation of complete virus inactivation}\par
Complete viral inactivation checked by inoculation of BHK cells incubated for two days and compared to the virus-infected cell (virus control) and normal cell (cell control). The inactivated virus showed monolayer of BHK cells and positive control showed viral cytopathic effect at 24-hour post-infection. Complete virus inactivation was obtained by 16hours for O / PanAsia2, A/Iran 05, SAT2/VII/Lib-12 (SAT2/ Lib), and SAT2/VII/Ghb-12(SAT2/Ghb) respectively. 
\section[{b) Measurement of Silver nanoparticles (AgNPs) size}]{b) Measurement of Silver nanoparticles (AgNPs) size}\par
Transmission Electron Microscopy (TEM) showed the particle size of the Silver nanoparticles (AgNPs) adjuvant of 5-10 nm as shown in the photo (  {\ref 1}) 
\section[{Photo (1): TEM micrograph of silver nanoparticles c) Testing of adjuvant cytotoxicity}]{Photo (1): TEM micrograph of silver nanoparticles c) Testing of adjuvant cytotoxicity}\par
The effect of Silver nanoparticles (AgNPs) adjuvant on the in vitro cell proliferation investigated in BHK cell line monolayers after its exposure to gradient concentrations of Silver nanoparticles (AgNPs) for 48 hours. The percentage of viable cells among all of the preparations was above 50\% indicating the safety of Silver nanoparticles (AgNPs) adjuvant. 
\section[{d) In vitro evaluation of cell-mediated immunity using lymphocyte proliferation (XTT) assay}]{d) In vitro evaluation of cell-mediated immunity using lymphocyte proliferation (XTT) assay}\par
The obtained results of cell mediated immune response using lymphocyte proliferation test for all animal groups expressed by Î?"OD (Delta Optical Density) were as follow: Group(A) showed Î?"OD (0.521) by using FMD viruses at 3 rd -day post-vaccination and reached its highest level (1.572) at 3 rd -week post-vaccination, then declined after nine weeks post-vaccination.\par
Group(B) showed Î?"OD (0.566) by using FMD viruses at 3 rdday post-vaccination and reached its highest level (1.660) at 3 rd -week post-vaccination then declined after ten weeks.\par
Group (C) showed Î?"OD (0.486) by using FMD viruses at 3 rd -day post-vaccination and reached its highest level (0.973) at 3 rd -week post-vaccination, then declined after seven weeks. These results are demonstrated in a table \hyperref[b0]{(1)} and fig \hyperref[b0]{(1)}.      {\ref 3})it is clear that protective FMD-ELISA antibody titers induced by AgNPs only started at the 1 st week post-vaccination with average values of 1.95, 1.93, 1.82 and 1.82 log 10 for type O, A, SAT2/ Lib and SAT2/Ghb respectively reaching their peak level at the 10 th week post-vaccination with average titers of 3.17, 3.17 Montaind ISA 206 oil vaccine induced FMD ELISA antibody titers started at the 2 nd week postvaccination with average values of 1.93, 1.97, 1.96 and 1.96 log 10 for type O, A, SAT2/ Lib and SAT2/Ghb respectively with peak levels at the10 th week postvaccination with average titers of 3.16, 3.06, 3.14 and 3.12 log10 respectively continued with protective level till the 36 th week then declined as shown in fig  {\ref (5, 6 \& 7)}. 
\section[{Delta optical density}]{Delta optical density} 
\section[{Weeks post-vaccination}]{Weeks post-vaccination}\par
Table \hyperref[b2]{(3)}: FMD ELISA antibody titer in vaccinated calves with the prepared polyvalent FMD vaccine formulae 
\section[{Group (A) =AgNPs vaccine}]{Group (A) =AgNPs vaccine}\par
Group (B) =oil and AgNPs vaccine.    
\section[{Discssion}]{Discssion}\par
Nanoparticle-containing vaccines have attracted tremendous interest in recent years, and a wide variety of nanoparticles have been developed and employed as delivery vehicles or immune potentiates, allowing an improvement of antigen stability but also the enhancement of antigen processing and immunogenicity \hyperref[b34]{(Smith et al., 2015)}.\par
The control of FMD in animals was considered to be important to effectively contain the disease in endemic areas so that vaccination of animals is effective in limiting the spread of FMD. So, this study aimed to improve the inactivated polyvalent FMD vaccine by adding Silver nitrate nanoparticles as an adjuvant.\par
Table \hyperref[b0]{(1)} showed that the results of cellmediated immune response using lymphocyte proliferation test for all animal groups expressed by Î?"OD appeared to be supported by \hyperref[b21]{Knudsen et al., (1979)} and \hyperref[b32]{Sharma et al., (1984)} who reported that cell-mediated immune response was a constitute of the immune response against FMD virus, and agreement-in some points with \hyperref[b26]{Mercedes et al.(1996)} The tabulated results in tables (2 \& 3) that SNT and ELISA titers for AgNPs, oil and AgNPs with oil FMD vaccine formulae agreed with \hyperref[b38]{Vahid et al. (2016)} who showed that adjuvant properties of AgNPs as a potent adjuvant induced higher antibody and the protective function is the production of neutralizing antibodies, either IgM or IgG, which are able to prevent the entry of the virus into cells. The results are supported also by \hyperref[b24]{Malyala and Singh (2010)} and \hyperref[b30]{Rebecca et al. (2010)}, who found that AgNPs might help the vaccine work more effectively, increasing antibody production, also agreed with \hyperref[b12]{Gurunathan et al., (2009)}; \hyperref[b19]{Kaba et al. (2009)}; \hyperref[b46]{Zhao et al. (2014)} and \hyperref[b7]{Daniel et al. (2019)}, who found that AgNPs improved B-cells function, mucosal and humoral immunity and protective activity also helped vaccine for induction of strong immunity when used as an adjuvant. The results also go in hand with the results obtained by \hyperref[b15]{Hamblin et al. (1986)}. They explained that the SNT measures those antibodies which neutralize the infectivity of FMD virion, while ELISA probably measures all classes of antibodies even those produced against incomplete and non-infectious virus.\par
Depending on the present obtained results we could conclud that the usage of Silver nitrate nanoparticles (AgNPs) with Montanid ISA 206 oil in inactivated FMD trivalent vaccine induces long-lasting immunity than that induced by oil adjuvant alone and improve both cellular and humoral immunity resulted in earlier and more long-lasting immunity the thing which can aid in companying to control FMD.\begin{figure}[htbp]
\noindent\textbf{8}\includegraphics[]{image-2.png}
\caption{\label{fig_0}8 .}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{11}\includegraphics[]{image-3.png}
\caption{\label{fig_1}11 .}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{1}\includegraphics[]{image-4.png}
\caption{\label{fig_2}Fig. ( 1}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{2}\includegraphics[]{image-5.png}
\caption{\label{fig_3}Fig. ( 2 Fig}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{}\includegraphics[]{image-6.png}
\caption{\label{fig_4}}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{5}\includegraphics[]{image-7.png}
\caption{\label{fig_6}Fig. ( 5 Fig}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{}\includegraphics[]{image-8.png}
\caption{\label{fig_7}}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{(} \par 
\begin{longtable}{P{0.20898345153664302\textwidth}P{0.14066193853427894\textwidth}P{0.14066193853427894\textwidth}P{0.2210401891252955\textwidth}P{0.13865248226950355\textwidth}}
Time Post-vaccination\tabcellsep \tabcellsep \tabcellsep \multicolumn{2}{l}{Î?"OD in buffy coat in vaccinated calves}\\
\tabcellsep Group (A)\tabcellsep Group (B)\tabcellsep Group (C)\tabcellsep Group (D)\\
Pre-vaccination\tabcellsep 0.056\tabcellsep 0.042\tabcellsep 0.046\tabcellsep 0.052\\
3 rd day\tabcellsep 0. 521\tabcellsep 0. 566\tabcellsep 0. 486\tabcellsep 0.066\\
1week\tabcellsep 0.863\tabcellsep 0.872\tabcellsep 0.495\tabcellsep 0.054\\
2 week\tabcellsep 1.450\tabcellsep 1.633\tabcellsep 0.971\tabcellsep 0.073\\
3 week\tabcellsep 1.572\tabcellsep 1.660\tabcellsep 0.973\tabcellsep 0.069\\
4 week\tabcellsep 1.265\tabcellsep 1.476\tabcellsep 0.731\tabcellsep 0.055\\
5 week\tabcellsep 0.862\tabcellsep 0.932\tabcellsep 0.685\tabcellsep 0.073\\
6 week\tabcellsep 0.674\tabcellsep 0.843\tabcellsep 0.642\tabcellsep 0.079\\
7 week\tabcellsep 0.621\tabcellsep 0.823\tabcellsep 0.502\tabcellsep 0.054\\
8 week\tabcellsep 0.565\tabcellsep 0.753\tabcellsep 0.462\tabcellsep 0.063\\
9 week\tabcellsep 0.532\tabcellsep 0.715\tabcellsep 0.374\tabcellsep 0.067\\
10 week\tabcellsep 0.404\tabcellsep 0.628\tabcellsep 0.336\tabcellsep 0.056\end{longtable} \par
  {\small\itshape [Note: Group (A)= AgNPs vaccine Group (B)= oil and AgNPs vaccine. Group (C)= oil adjuvant vaccine. Group (D)=control group.]} 
\caption{\label{tab_0}Table ( 1}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{} \par 
\begin{longtable}{P{0.1823170731707317\textwidth}P{0.04573170731707317\textwidth}P{0.03414634146341463\textwidth}P{0.08414634146341464\textwidth}P{0.039634146341463415\textwidth}P{0.039634146341463415\textwidth}P{0.043292682926829265\textwidth}P{0.1225609756097561\textwidth}P{0.039634146341463415\textwidth}P{0.05792682926829268\textwidth}P{0.035975609756097565\textwidth}P{0.025609756097560974\textwidth}P{0.03841463414634146\textwidth}P{0.06097560975609755\textwidth}}
\multicolumn{7}{l}{vaccination with average values of 1.65, 1.5, 1.5 and 1.5}\tabcellsep \multicolumn{7}{l}{with average titers of 2.8, 2.7, 2.7 and 2.5log 10 and}\\
\multicolumn{7}{l}{log 10 for type O, A, SAT2/ Lib and SAT2/Ghb respectively}\tabcellsep \multicolumn{7}{l}{continued with protective level till 36 weeks then}\\
\multicolumn{7}{l}{reaching their peak level at 10 th -weeks post-vaccination}\tabcellsep \multicolumn{5}{l}{declined as shown in fig (2, 3 \& 4).}\tabcellsep \tabcellsep \\
\tabcellsep \tabcellsep \tabcellsep \multicolumn{10}{l}{FMD serum neutralizingantibody titer (log10) in vaccinated calve groups}\tabcellsep \\
Time post-vaccination\tabcellsep \tabcellsep \multicolumn{2}{l}{Group (A)}\tabcellsep \tabcellsep \tabcellsep \multicolumn{2}{l}{Group (B)}\tabcellsep \tabcellsep \tabcellsep \multicolumn{2}{l}{Group (C)}\tabcellsep \tabcellsep group D\\
\tabcellsep O\tabcellsep A\tabcellsep SAT2 /lib\tabcellsep SAT2 /Ghb\tabcellsep O\tabcellsep A\tabcellsep SAT2 / lib\tabcellsep SAT2/ Ghb\tabcellsep O\tabcellsep A\tabcellsep SAT2 /lib\tabcellsep SAT2/ Ghb\tabcellsep \\
0\tabcellsep \multicolumn{2}{l}{0.15 0.15}\tabcellsep 0.3\tabcellsep 0.3\tabcellsep \multicolumn{2}{l}{0.15 0.15}\tabcellsep 0.3\tabcellsep 0.3\tabcellsep 0\tabcellsep 0.3\tabcellsep 0.3\tabcellsep 0.15\tabcellsep 0.15\\
1 week\tabcellsep 1.65\tabcellsep 1.5\tabcellsep 1.5\tabcellsep 1.5\tabcellsep 1. 4\tabcellsep \multicolumn{2}{l}{1.35 1.35}\tabcellsep 1.2\tabcellsep 1.2\tabcellsep \multicolumn{2}{l}{1.2 1.05}\tabcellsep 0.9\tabcellsep 0.15\\
2week\tabcellsep 1.8\tabcellsep 1.8\tabcellsep 1.7\tabcellsep 1.7\tabcellsep 1.95\tabcellsep 1.8\tabcellsep 1.8\tabcellsep 1.7\tabcellsep 1.65\tabcellsep 1.5\tabcellsep 1.5\tabcellsep 1.5\tabcellsep 0.15\\
3 week\tabcellsep 2.4\tabcellsep 2.25\tabcellsep 2.25\tabcellsep 2.1\tabcellsep 2.4\tabcellsep 2.4\tabcellsep 2.25\tabcellsep 2.25\tabcellsep \multicolumn{3}{l}{1.95 1.95 1.8}\tabcellsep 1.8\tabcellsep 0.15\\
4 week\tabcellsep \multicolumn{2}{l}{2.55 2.55}\tabcellsep 2.4\tabcellsep 2.25\tabcellsep 2.55\tabcellsep 2.4\tabcellsep 2.25\tabcellsep 2.1\tabcellsep 2.1\tabcellsep 2.2\tabcellsep 2.1\tabcellsep 2.1\tabcellsep 0.45\\
6 week\tabcellsep 2.8\tabcellsep 2.7\tabcellsep 2. 5\tabcellsep 2.5\tabcellsep 2.7\tabcellsep 2.7\tabcellsep 2.55\tabcellsep 2.5\tabcellsep 2.4\tabcellsep \multicolumn{2}{l}{2.25 2.1}\tabcellsep 2.1\tabcellsep 0.45\\
8 week\tabcellsep \multicolumn{2}{l}{2.85 2.85}\tabcellsep 2.7\tabcellsep 2.55\tabcellsep 2.85\tabcellsep 2.7\tabcellsep 2.7\tabcellsep 2.5\tabcellsep 2.4\tabcellsep 2.4\tabcellsep 2.4\tabcellsep 2.25\tabcellsep 0.45\\
10 week\tabcellsep 3.0\tabcellsep 3.0\tabcellsep 2.85\tabcellsep 2.7\tabcellsep 3.0\tabcellsep 3.0\tabcellsep 2.85\tabcellsep 2.85\tabcellsep 2.8\tabcellsep 2.7\tabcellsep 2.7\tabcellsep 2.5\tabcellsep 0.45\\
12 week\tabcellsep 2.85\tabcellsep 2.7\tabcellsep 2.5\tabcellsep 2.4\tabcellsep 2.85\tabcellsep 2.7\tabcellsep 2.5\tabcellsep 2.4\tabcellsep 2.4\tabcellsep 2.4\tabcellsep 2.4\tabcellsep 2.25\tabcellsep 0.3 D D D D\\
14 week\tabcellsep 2.7\tabcellsep 2.55\tabcellsep 2.4\tabcellsep 2.25\tabcellsep 2.7\tabcellsep 2.5\tabcellsep 2.4\tabcellsep 2.4\tabcellsep 2.25\tabcellsep 2.1\tabcellsep 2.1\tabcellsep 2.1\tabcellsep 0.3\\
16 week\tabcellsep 2.5\tabcellsep 2.55\tabcellsep 2.4\tabcellsep 2.1\tabcellsep 2.5\tabcellsep 2.4\tabcellsep 2.2\tabcellsep 2.25\tabcellsep 2.25\tabcellsep 2.1\tabcellsep 2.1\tabcellsep 2.1\tabcellsep 0.3\\
20 week\tabcellsep 2.5\tabcellsep 2.4\tabcellsep 2.25\tabcellsep 1.95\tabcellsep 2.4\tabcellsep 2.4\tabcellsep 2.1\tabcellsep 2.1\tabcellsep \multicolumn{3}{l}{1.95 1.95 1.8}\tabcellsep 1.8\tabcellsep 0.3\\
24 week\tabcellsep 2.25\tabcellsep 2.1\tabcellsep 1.8\tabcellsep 1.65\tabcellsep 2.4\tabcellsep 2.25\tabcellsep 2.1\tabcellsep 2.1\tabcellsep 1.95\tabcellsep 1.8\tabcellsep 1.8\tabcellsep 1.8\tabcellsep 0.3\\
28 week\tabcellsep 1.95\tabcellsep 1.8\tabcellsep 1.65\tabcellsep 1.5\tabcellsep 2.25\tabcellsep 2.1\tabcellsep 1.95\tabcellsep 1.95\tabcellsep 1.8\tabcellsep 1.8\tabcellsep 1.7\tabcellsep 1.7\tabcellsep 0.15\\
32 week\tabcellsep 1.65\tabcellsep 1.5\tabcellsep 1.5\tabcellsep 1.4\tabcellsep 1.95\tabcellsep 1.8\tabcellsep 1.8\tabcellsep 1.65\tabcellsep \multicolumn{3}{l}{1.65 1.65 1.5}\tabcellsep 1.5\tabcellsep 0.15\\
36 week\tabcellsep 1.4\tabcellsep 1.35\tabcellsep 1.35\tabcellsep 1.2\tabcellsep 1.8\tabcellsep \multicolumn{2}{l}{1.65 1.65}\tabcellsep 1.5\tabcellsep 1.65\tabcellsep 1.5\tabcellsep 1.4\tabcellsep 1.5\tabcellsep 0.15\\
40 week\tabcellsep 1.2\tabcellsep 1.2\tabcellsep 1.05\tabcellsep 0.9\tabcellsep 1.5\tabcellsep 1.5\tabcellsep 1.5\tabcellsep 1.4\tabcellsep \multicolumn{3}{l}{1.35 1.35 1.2}\tabcellsep 1.2\tabcellsep 0.15\\
\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep © 2020 Global Journals\end{longtable} \par
  {\small\itshape [Note: Group (A) Silver nitrateGroup (B) Silver nitrate + Oil Group (C) Oil Group (D) ControlTable (2): FMD serum neutralizing antibody titers in calves vaccinated with inactivated FMD polyvalent Group (A) =AgNPs vaccine Group (B) =oil and AgNPs vaccine. Group (C) =oil vaccine. Group (D) =control group.]} 
\caption{\label{tab_1}}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{} \par 
\begin{longtable}{P{0.1301470588235294\textwidth}P{0.021323529411764703\textwidth}P{0.05073529411764706\textwidth}P{0.10661764705882353\textwidth}P{0.055882352941176466\textwidth}P{0.05073529411764706\textwidth}P{0.05661764705882352\textwidth}P{0.05661764705882352\textwidth}P{0.05661764705882352\textwidth}P{0.051470588235294115\textwidth}P{0.05735294117647059\textwidth}P{0.05661764705882352\textwidth}P{0.0551470588235294\textwidth}P{0.044117647058823525\textwidth}}
\tabcellsep \tabcellsep \tabcellsep \multicolumn{8}{l}{FMD ELISA antibody titer (log10) of vaccinated calve groups}\tabcellsep \tabcellsep \tabcellsep \\
Time post-\tabcellsep \tabcellsep \tabcellsep Group (A)\tabcellsep \tabcellsep \tabcellsep \multicolumn{2}{l}{Group (B)}\tabcellsep \tabcellsep \tabcellsep \multicolumn{2}{l}{Group (C)}\tabcellsep \tabcellsep \\
vaccination\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep Group\\
\tabcellsep O\tabcellsep A\tabcellsep SAT2 /lib\tabcellsep SAT2/Ghb\tabcellsep O\tabcellsep A\tabcellsep SAT2/ lib\tabcellsep SAT2/ Ghb\tabcellsep O\tabcellsep A\tabcellsep SAT2 /lib\tabcellsep SAT2/Ghb\tabcellsep D\\
0\tabcellsep 0.21\tabcellsep 0.18\tabcellsep 0.18\tabcellsep 0.27\tabcellsep 0.26\tabcellsep 0.24\tabcellsep 0.22\tabcellsep 0.25\tabcellsep 0.12\tabcellsep 0.28\tabcellsep 0.19\tabcellsep 0.3\tabcellsep 0.6\\
1 week\tabcellsep 1.95\tabcellsep 1.93\tabcellsep 1.82\tabcellsep 1.82\tabcellsep 1.77\tabcellsep 1.73\tabcellsep 1.68\tabcellsep 1.66\tabcellsep 1.55\tabcellsep 1.55\tabcellsep 1.50\tabcellsep 1.50\tabcellsep 0.6\\
2week\tabcellsep 2.18\tabcellsep 2.18\tabcellsep 2.14\tabcellsep 2.14\tabcellsep 1.98\tabcellsep 1.97\tabcellsep 1.95\tabcellsep 1.93\tabcellsep 1.93\tabcellsep 1.97\tabcellsep 1.96\tabcellsep 1.96\tabcellsep 0.6\\
3 week\tabcellsep 2.55\tabcellsep 2.52\tabcellsep 2.54\tabcellsep 2.50\tabcellsep 2.72\tabcellsep 2.70\tabcellsep 2.62\tabcellsep 2.60\tabcellsep 2.19\tabcellsep 2.19\tabcellsep 2.15\tabcellsep 2.13\tabcellsep 0.6\\
4 week\tabcellsep 2.75\tabcellsep 2.70\tabcellsep 2.68\tabcellsep 2.64\tabcellsep 2.85\tabcellsep 2,85\tabcellsep 2.78\tabcellsep 2.76\tabcellsep 2.42\tabcellsep 2.43\tabcellsep 2.40\tabcellsep 2.42\tabcellsep 0.6\\
6 week\tabcellsep 2.87\tabcellsep 2.80\tabcellsep 2.78\tabcellsep 2.70\tabcellsep 2.90\tabcellsep 2.88\tabcellsep 2.88\tabcellsep 2.78\tabcellsep 2.49\tabcellsep 2.48\tabcellsep 2.46\tabcellsep 2.43\tabcellsep 0.75\\
8 week\tabcellsep 2.96\tabcellsep 2.88\tabcellsep 2.80\tabcellsep 2.78\tabcellsep 2.94\tabcellsep 2.98\tabcellsep 2.97\tabcellsep 2.90\tabcellsep 2.86\tabcellsep 2.75\tabcellsep 2.74\tabcellsep 2.73\tabcellsep 0.75\\
\multicolumn{2}{l}{10 week 3.17}\tabcellsep 3.17\tabcellsep 3.14\tabcellsep 3.14\tabcellsep 3.37\tabcellsep 3.32\tabcellsep 3.25\tabcellsep 3.25\tabcellsep 3.16\tabcellsep 3.06\tabcellsep 3.14\tabcellsep 3.12\tabcellsep 0.75\\
\multicolumn{2}{l}{12 week 3.19}\tabcellsep 3.17\tabcellsep 3.16\tabcellsep 3.14\tabcellsep 3.25\tabcellsep 3.25\tabcellsep 3.18\tabcellsep 3.18\tabcellsep 2.9 8\tabcellsep 2.95\tabcellsep 2.92\tabcellsep 2.93\tabcellsep 0.9\\
\multicolumn{2}{l}{14 week 2.86}\tabcellsep 2.82\tabcellsep 2,78\tabcellsep 2.76\tabcellsep 2.97\tabcellsep 2.95\tabcellsep 2.84\tabcellsep 2.80\tabcellsep 2.58\tabcellsep 2.57\tabcellsep 2.54\tabcellsep 2.55\tabcellsep 0.9\\
\multicolumn{2}{l}{16 week 2.74}\tabcellsep 2.74\tabcellsep 2.68\tabcellsep 2.73\tabcellsep 2.88\tabcellsep 2.87\tabcellsep 2.84\tabcellsep 2.80\tabcellsep 2.48\tabcellsep 2.45\tabcellsep 2.41\tabcellsep 2.43\tabcellsep 0.9\\
\multicolumn{2}{l}{20 week 2.52}\tabcellsep 2.48\tabcellsep 2.42\tabcellsep 2.37\tabcellsep 2.68\tabcellsep 2.62\tabcellsep 2.63\tabcellsep 2.63\tabcellsep 2.38\tabcellsep 2.36\tabcellsep 2.32\tabcellsep 2.28\tabcellsep 0.6\\
\multicolumn{2}{l}{24 week 2.35}\tabcellsep 2.29\tabcellsep 2.28\tabcellsep 2.27\tabcellsep 2.49\tabcellsep 2.46\tabcellsep 2.44\tabcellsep 2.46\tabcellsep 2.17\tabcellsep 2.14\tabcellsep 2.14\tabcellsep 2.10\tabcellsep 0.6\\
\multicolumn{2}{l}{28 week 2.15}\tabcellsep 2.12\tabcellsep 2.12\tabcellsep 2.10\tabcellsep 2.28\tabcellsep 2.28\tabcellsep 2.25\tabcellsep 2.25\tabcellsep 1.96\tabcellsep 1.93\tabcellsep 1.93\tabcellsep 1.90\tabcellsep 0.6\\
\multicolumn{2}{l}{32 week 1.94}\tabcellsep 1.90\tabcellsep 1.85\tabcellsep 1.84\tabcellsep 2.18\tabcellsep 2.16\tabcellsep 2.15\tabcellsep 2.10\tabcellsep 1.92\tabcellsep 1.90\tabcellsep 1.87\tabcellsep 1.88\tabcellsep 0.3\\
\multicolumn{2}{l}{36 week 1.73}\tabcellsep 1.73\tabcellsep 1.68\tabcellsep 1.62\tabcellsep 1.98\tabcellsep 1.96\tabcellsep 1.96\tabcellsep 1.92\tabcellsep 1.47\tabcellsep 1.42\tabcellsep 1.42\tabcellsep 1.40\tabcellsep 0.3\\
\multicolumn{2}{l}{40 week 1.64}\tabcellsep 1.63\tabcellsep 1.52\tabcellsep 1.52\tabcellsep 1.92\tabcellsep 195\tabcellsep 1.93\tabcellsep 1.90\tabcellsep 1.42\tabcellsep 1.38\tabcellsep 1.35\tabcellsep 1.35\tabcellsep 0.3\end{longtable} \par
 
\caption{\label{tab_2}}\end{figure}
 		 		\backmatter  			  				\begin{bibitemlist}{1}
\bibitem[ Influenza Infection Through Inducing BALT and IgAmediated Mucosal Immunity. Biomaterials]{b8}\label{b8} 	 		\textit{},  	 	 		\textit{Influenza Infection Through Inducing BALT and IgAmediated Mucosal Immunity. Biomaterials}  		217 p. 119308.  	 
\bibitem[Hamblin et al. ()]{b15}\label{b15} 	 		‘A new enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies against foot-andmouth disease virus. I. Development and method of ELISA’.  		 			C Hamblin 		,  		 			Barnett 		,  		 			R S Hedger 		.  	 	 		\textit{J Immunol Methods}  		1986. 93  (1)  p. .  	 
\bibitem[Kaba et al. ()]{b19}\label{b19} 	 		‘A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria’.  		 			S A Kaba 		,  		 			C Brando 		,  		 			Q Guo 		,  		 			C Mittelholzer 		,  		 			S Raman 		,  		 			D Tropel 		.  	 	 		\textit{J Immunol}  		2009. 183 p. .  	 
\bibitem[Bahnemann ()]{b2}\label{b2} 	 		‘Binary ethylenimine as an inactivant for foot-and-mouth disease virus and its application for vaccine production’.  		 			H G Bahnemann 		.  	 	 		\textit{Arch Virol}  		1975. 47 p. .  	 
\bibitem[Perni et al. ()]{b29}\label{b29} 	 		‘Biogenic Synthesis of Silver Nanoparticles Capped with L-cysteine’.  		 			S V Perni 		,  		 			P Hakala 		,  		 			Prokopovich 		.  	 	 		\textit{Colloids Surf. A}  		2014. 460 p. .  	 
\bibitem[Sonia et al. ()]{b35}\label{b35} 	 		‘Comparative study of T cell proliferative response in calves vaccinated with FMD vaccine using Cell titer-Aqueous one solution non radioactive assay (MTS).Zag’.  		 			A Sonia 		,  		 			Rizk 		,  		 			M Hiam 		,  		 			Abu-Elnaga H I Fakhry 		.  	 	 		\textit{Vet. J}  		 1110- 1458.  		2010. 38  (4)  p. .  	 
\bibitem[Yen et al. ()]{b43}\label{b43} 	 		‘Cytotoxicity and Immunological Response of Gold and Silver Nanoparticles of Different Sizes’.  		 			H J Yen 		,  		 			S H Hsu 		,  		 			C L Tsai 		.  	 	 		\textit{Small}  		2009. 5  (13)  p. .  	 
\bibitem[Grubman ()]{b13}\label{b13} 	 		‘Development of novel strategies to control foot-and-mouth disease: marker vaccines and antivirals’.  		 			M J Grubman 		.  	 	 		\textit{Biologicals}  		2005. 33 p. .  	 
\bibitem[Sulic et al. ()]{b36}\label{b36} 	 		‘Drtermination of cell growth and malignant transformation’.  		 			S Sulic 		,  		 			L Panic 		,  		 			L Dikic 		.  	 	 		\textit{Croat Med. J}  		2005. 46  (4)  p. .  	 
\bibitem[Frial et al. ()]{b10}\label{b10} 	 		‘Effect of silver nanoparticles that extracted by Staphylococcus aureuson cellular immunity in rabbits’.  		 			G A Frial 		,  		 			A Lubna 		,  		 			F Ayad 		,  		 			Al 		.  	 	 		\textit{J. Pharm. Sci. \& Res}  		2018. 10  (6)  p. .  	 
\bibitem[Voller et al. ()]{b40}\label{b40} 	 		‘Enzyme immune assay in diagnostic medicine, theory and practice’.  		 			A Voller 		,  		 			D E Bidwell 		,  		 			Ann Bartlett 		.  	 	 		\textit{Bull. World Health Org}  		1976. 53 p. .  	 
\bibitem[Xu et al. ()]{b44}\label{b44} 	 		‘Evaluation of the adjuvant effect of silver nanoparticles both in vitro and in vivo’.  		 			Y Xu 		,  		 			H Tang 		,  		 			J H Liu 		,  		 			H Wang 		,  		 			Y Liu 		.  	 	 		\textit{ToxicolLett}  		2013. 219  (10)  p. .  	 
\bibitem[Ferreira ()]{b11}\label{b11} 	 		 			M E V Ferreira 		.  		 21/22.  		\textit{Prubade microneutralization poraestudies de anticueropos de la fibreafsta 13th CentropanamericanoFiebreAftosa},  				1976. p. .  	 
\bibitem[Batista et al. ()]{b4}\label{b4} 	 		\textit{First-principles investigation of electrochemical properties of gold nanoparticles},  		 			J C Batista 		,  		 			Ronaldo 		,  		 			S Mário 		,  		 			H Mazzoni 		,  		 			Chacham 		.  		2010.  	 
\bibitem[Sharma ()]{b32}\label{b32} 	 		‘Foot and mouth disease in sheep and goats’.  		 			Sharma 		.  	 	 		\textit{Vet. Res. J}  		1984. 1981. 4  (1)  p. .  	 
\bibitem[Mj and Baxt ()]{b14}\label{b14} 	 		‘Foot-and-mouth disease’.  		 			Grubman Mj 		,  		 			B Baxt 		.  	 	 		\textit{Clin. Microbiol Rev}  		2004. 17  (2)  p. .  	 
\bibitem[Barnett et al. ()]{b3}\label{b3} 	 		‘Foot-and-mouth disease vaccine potency testing: determination and statistical validation of a model using a serological approach’.  		 			P V Barnett 		,  		 			R J Statham 		,  		 			W Vosloo 		,  		 			D T Haydon 		.  	 	 		\textit{Vaccine}  		2003. 4  (23)  p. .  	 
\bibitem[Wong et al. ()]{b42}\label{b42} 	 		‘Further evidence of the anti-inflammatory effects of silver nanoparticles’.  		 			K K Wong 		,  		 			S O Cheung 		,  		 			L Huang 		,  		 			J Niu 		,  		 			C Tao 		,  		 			C M Ho 		,  		 			C M Che 		,  		 			P K Tam 		.  	 	 		\textit{Chem. Med. Chem}  		2009. 4  (7)  p. .  	 
\bibitem[Vahid et al. ()]{b38}\label{b38} 	 		‘Green synthesis and evaluation of silver nanoparticles as adjuvant in rabies veterinary vaccine’.  		 			A Vahid 		,  		 			S Alireza 		,  		 			B A Fahimeh 		,  		 			S A Sadat 		,  		 			S Mohammad 		,  		 			S K Alirezaj 		,  		 			B Razieh 		,  		 			B Rouzbeh 		,  		 			RezaA C 		.  	 	 		\textit{Int. J Nanomedicine}  		2016. 11 p. .  	 
\bibitem[Singh et al. ()]{b33}\label{b33} 	 		‘Green synthesis of silver nanoparticles using Argimonemexicana leaf extract and evaluation of their antimicrobial activities’.  		 			A Singh 		,  		 			D Jain 		,  		 			M K Upadhyay 		,  		 			N Khandelwal 		,  		 			H N Verma 		.  	 	 		\textit{Digest J. Nanometer. Biostruct}  		2010. 5  (2)  p. .  	 
\bibitem[Gurunathan et al. ()]{b12}\label{b12} 	 		 			S Gurunathan 		,  		 			K J Lee 		,  		 			K Kalishwaralal 		,  		 			S Sheikpranbabu 		,  		 			R Vaidyanathan 		,  		 			S H Eom 		.  	 	 		\textit{Antiangiogenic properties of silver nanoparticles},  				2009. 30 p. .  	 
\bibitem[Wael Mossad Gamal El-Din, Ehab El-Sayed Ibrahim, Hind Daoud and Samir Mohamed Ali ()]{b41}\label{b41} 	 		‘Humeral and cellular immune response of Egyptian trivalent foot and mouth disease oil vaccine in sheep’.  	 	 		\textit{Res. Opin. Anim. Vet. Sci}  		Wael Mossad Gamal El-Din, Ehab El-Sayed Ibrahim, Hind Daoud and Samir Mohamed Ali (ed.)  		2014. 4  (4)  p. .  	 
\bibitem[Knudsen et al. ()]{b21}\label{b21} 	 		‘Immunity to foot-and-mouth disease virus in guinea pigs: clinical and immune responses’.  		 			R C Knudsen 		,  		 			C M Groocock 		,  		 			A A Aaderson 		.  	 	 		\textit{Infection and Immunity}  		1979. 24 p. .  	 
\bibitem[Hiam et al. ()]{b16}\label{b16} 	 		‘Immunological studies on bivalent foot and mouth disease vaccine using purified and concentrated virus’.  		 			M Hiam 		,  		 			Fakhry 		,  		 			M Eman 		,  		 			El-Garf 		.  	 	 		\textit{J. Egypt. Vet. Med. Asso}  		2010. 70 p. .  	 
\bibitem[Castellheim et al. ()]{b6}\label{b6} 	 		‘Innate immune responses to danger signals in systemic inflammatory response syndrome and sepsis’.  		 			A Castellheim 		,  		 			O L Brekke 		,  		 			T Espevik 		,  		 			M Harboe 		,  		 			T E Mollnes 		.  	 	 		\textit{Scand. J Immunol}  		2009. 69  (6)  p. .  	 
\bibitem[Venier et al. ()]{b39}\label{b39} 	 		‘Innate-immunity cytokines induced by very small size proteoliposomes, a Neisseria-derived Immunological adjuvant’.  		 			C Venier 		,  		 			M D Guthmann 		,  		 			L E Fernandez 		,  		 			L Fainboim 		.  	 	 		\textit{ClinExpImmunol}  		2007. 147  (2)  p. .  	 
\bibitem[Zhang et al. ()]{b45}\label{b45} 	 		‘Interleukin-10 production at the early stage of infection with foot-and-mouth disease virus related to the likelihood of persistent infection in cattle’.  		 			Z Zhang 		,  		 			C Doel 		,  		 			B John 		,  		 			Bashiruddin 		.  	 	 		\textit{Vet Res}  		2015. 46 p. 132.  	 
\bibitem[Manual of diagnostic tests and vaccine terrestrial animals. WRLFMD Quarterly Report (2012)]{b27}\label{b27} 	 	 	 		\textit{Manual of diagnostic tests and vaccine terrestrial animals. WRLFMD Quarterly Report},  				2012. April-June 2012.  	 
\bibitem[Malyala and Singh ()]{b24}\label{b24} 	 		‘Micro/nanoparticle adjuvants: preparation and formulation with antigens’.  		 			P Malyala 		,  		 			M Singh 		.  	 	 		\textit{Methods in molecular biology}  		2010. 626 p. .  	 
\bibitem[Ismail et al. ()]{b17}\label{b17} 	 		‘Optimization of the Inactivation Process of FMD Virus Serotype SAT-2 by Binary Ethyleneimine (BEI)’.  		 			A H Ismail 		,  		 			S A El-Mahdy 		,  		 			W G Mossad 		,  		 			Abd El-Krim 		,  		 			AS 		,  		 			Abou El-Yazid 		,  		 			M 		,  		 			AliS M 		.  	 	 		\textit{J Vet Adv}  		2013. 201  (3)  p. .  	 
\bibitem[Pacheco et al. ()]{b28}\label{b28} 	 		‘Persistent Foot-and-Mouth Disease Virus Infection in the Nasopharynx of Cattle; Tissue-Specific Distribution and Local Cytokine Expression’.  		 			J M Pacheco 		,  		 			G R Smoliga 		,  		 			O' Donnell 		,  		 			V Brito 		,  		 			B P Stenfeldt 		,  		 			C 		,  		 			Rodriguez Ll 		,  		 			J Arzt 		.  	 	 		\textit{PLoS One}  		2015. 10  (5)  p. e0125698.  	 
\bibitem[Pierre et al. ()]{b7}\label{b7} 	 		 			Daniel S G Pierre 		,  		 			L G Berengere 		,  		 			V Nuria 		,  		 			S Remi 		,  		 			L B Alice 		,  		 			G Alix 		,  		 			K Bruno 		,  		 			C Jean 		,  		 			MS 		,  		 			IgnacioG V 		.  		\textit{Silver Nanoparticle-Adjuvanted Vaccine Protects Against Lethal},  				2019. 2020. 9.  	 
\bibitem[Macpherson and Stocher ()]{b23}\label{b23} 	 		‘Polyma transformation hamster cell clones, an investigation of genetic factors affecting cell competence’.  		 			M Macpherson 		,  		 			B Stocher 		.  	 	 		\textit{Virology}  		1962. 16 p. .  	 
\bibitem[Mercedes et al. ()]{b26}\label{b26} 	 		‘Recognition of foot-and-mouth disease virus and its capsid protein VP1 by bovine peripheral T lymphocytes’.  		 			G V Mercedes 		,  		 			D Timothy 		,  		 			C Trevor 		,  		 			R Martin 		,  		 			E P Michael 		.  	 	 		\textit{J Gen Virol}  		1996. 77 p. .  	 
\bibitem[El-Watany et al. ()]{b9}\label{b9} 	 		‘Relationship between cellular and humoral immunity responses in animal vaccinated with FMD vaccine.Zag’.  		 			H El-Watany 		,  		 			M M Shawky 		,  		 			O M Roshdy 		,  		 			S El-Kelany 		.  		 LSSN 1110-1458.  	 	 		\textit{Vet.J}  		1999. 27  (1) .  	 
\bibitem[Lázaro et al. ()]{b22}\label{b22} 	 		‘Role of Metallic Nanoparticles in Vaccinology: Implications for Infectious Disease Vaccine Development’.  		 			M M Lázaro 		,  		 			K André 		,  		 			P J Ana 		.  		 \xref{http://dx.doi.org/10.3389/fimmu.2017.00239}{10.3389/fimmu.2017.00239}.  		 \url{https://doi.org/10.3389/fimmu.2017.00239}  	 	 		\textit{Front. Immunol}  		2017. 08.  	 
\bibitem[Rebecca et al. ()]{b30}\label{b30} 	 		\textit{Silver Nanoparticles Interactions with the Immune System: Implications for Health and Disease},  		 			K Rebecca 		,  		 			F M Rafael 		,  		 			M C Paula 		,  		 			Ana Paula 		,  		 			Z 		,  		 			David Pozo 		.  		 \xref{http://dx.doi.org/10.5772/8511Corpus}{10.5772/8511Corpus}.  		 ID: 16094505.  		2010.  	 
\bibitem[Smith et al. ()]{b34}\label{b34} 	 		 			J D Smith 		,  		 			L D Morton 		,  		 			B D Ulery 		.  	 	 		\textit{Nanoparticles as synthetic vaccines},  				2015. 34 p. .  	 
\bibitem[Mansour ()]{b25}\label{b25} 	 		\textit{Some studies on the effect of mycotoxins on immune response of FMD vaccinated animals},  		 			A Mansour 		.  		2001.  		 			Infectious Diseases). Fac.Vet.Med., Cairo University 		 	 	 (Ph.D. Thesis) 
\bibitem[Samir ()]{b31}\label{b31} 	 		\textit{Studies on preparation of newly oil adjuvanted FMD vaccine},  		 			M A A Samir 		.  		2002.  		 			Virology) Fac. Vet. Med. Cairo University 		 	 	 (Ph.D. Thesis) 
\bibitem[Udapudi et al. ()]{b37}\label{b37} 	 		‘Synthesis and characterization of Silver nanoparticles’.  		 			B Udapudi 		,  		 			Praveen Kumar Naik 		,  		 			Sabiha Tabassum Savadatti 		,  		 			Rupali Sharma 		,  		 			Samprita Balgi 		.  	 	 		\textit{International Journal of Pharmacy and Biological Sciences}  		2012. 2 p. .  	 
\bibitem[Shin et al. ()]{b18}\label{b18} 	 		‘The effects of nano-silver on the proliferation and cytokine expression by peripheral blood mononuclear cells’.  		 			S H Shin 		,  		 			M K Ye 		,  		 			H S Kim 		,  		 			H S Kang 		.  	 	 		\textit{Int.Immunopharmacol}  		2007. 7  (13)  p. .  	 
\bibitem[Brown ()]{b5}\label{b5} 	 		‘The history of research in foot and-mouth disease’.  		 			F Brown 		.  	 	 		\textit{Virus Res}  		2003. 91 p. .  	 
\bibitem[Alexandersen et al. ()]{b0}\label{b0} 	 		‘The pathogenesis and diagnosis of footand mouth disease’.  		 			S Alexandersen 		,  		 			Z Zhang 		,  		 			A I Donaldson 		,  		 			A J Garland 		.  	 	 		\textit{J Comp Pathol}  		2003. 129  (1)  p. .  	 
\bibitem[Arzt et al. ()]{b1}\label{b1} 	 		‘The pathogenesis of foot-and-mouth disease I: viral pathways in cattle’.  		 			J Arzt 		,  		 			N Juleff 		,  		 			Z Zhang 		,  		 			L L Rodriguez 		.  	 	 		\textit{TransboundEmerg}  		2011. 58  (4)  p. .  	 
\bibitem[Killington et al. ()]{b20}\label{b20} 	 		‘Virus purification’.  		 			R A Killington 		,  		 			A Stokes 		,  		 			J C Hierholzer 		.  	 	 		\textit{Virology Methods Manual},  				 			B W J Mahy,  			H O Kangro 		 (ed.)  		 (New York)  		1996. Academic Press. p. .  	 
\bibitem[Zhao et al. ()]{b46}\label{b46} 	 		 			L Zhao 		,  		 			A Seth 		,  		 			N Wibowo 		,  		 			C Zhao 		,  		 			Mittern 		,  		 			C Yu 		,  		 			Anton P J Middelberg 		.  	 	 		\textit{Nanoparticle vaccines},  				2014. 32 p. .  	 
\end{bibitemlist}
 			 		 	 
\end{document}
